T-cell
acute lymphoblastic leukemia (
T-ALL) and T-cell acute
lymphoblastic lymphoma (T-LBL) are aggressive
hematological malignancies that are currently treated with high-dose
chemotherapy. Over the last several years, the search toward novel and less-toxic therapeutic strategies for
T-ALL/T-LBL patients has largely focused on the identification of cell-intrinsic properties of the
tumor cell. However, non-cell-autonomous activation of specific oncogenic pathways might also offer opportunities that could be exploited at the therapeutic level. In line with this, we here show that endogenous
interleukin 7 (
IL7) can increase the expression of the oncogenic
kinase proviral integration site for Moloney-murine
leukemia 1 (PIM1) in CD127+
T-ALL/T-LBL, thereby rendering these
tumor cells sensitive to in vivo PIM inhibition. In addition, using different CD127+
T-ALL/T-LBL xenograft models, we also reveal that
residual tumor cells, which remain present after short-term in vivo
chemotherapy, display consistent upregulation of PIM1 as compared with bulk nontreated
tumor cells. Notably, this effect was transient as increased PIM1 levels were not observed in reestablished disease after abrogation of the initial
chemotherapy. Furthermore, we uncover that this phenomenon is, at least in part, mediated by the ability of
glucocorticoids to cause transcriptional upregulation of IL7RA in
T-ALL/T-LBL patient-derived xenograft (PDX) cells, ultimately resulting in non-cell-autonomous PIM1 upregulation by endogenous
IL7. Finally, we confirm in vivo that
chemotherapy in combination with a pan-PIM inhibitor can improve
leukemia survival in a PDX model of CD127+
T-ALL. Altogether, our work reveals that
IL7 and
glucocorticoids coordinately drive aberrant activation of PIM1 and suggests that IL7-responsive CD127+
T-ALL and T-LBL patients could benefit from PIM inhibition during
induction chemotherapy.